-
公开(公告)号：US5514577A
公开(公告)日：1996-05-07
申请号：US31147
申请日：1993-03-12
申请人： Kenneth G. Draper , Stanley T. Crooke , Christopher K. Mirabelli , David J. Ecker , Ronnie C. Hanecak , Kevin P. Anderson , Vickie L. Brown-Driver , Jacqueline R. Wyatt
发明人： Kenneth G. Draper , Stanley T. Crooke , Christopher K. Mirabelli , David J. Ecker , Ronnie C. Hanecak , Kevin P. Anderson , Vickie L. Brown-Driver , Jacqueline R. Wyatt
IPC分类号： C12N15/09 , A61K31/70 , A61K31/7088 , A61K38/00 , A61P31/12 , A61P31/22 , C07H21/00 , C07H21/04 , C07K14/03 , C12N15/113 , C12N15/117 , C12Q1/70 , C12N7/06
CPC分类号： C12N15/1133 , A61K31/70 , C07H21/00 , C07K14/005 , C12N15/1137 , C12N15/117 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , A61K38/00 , C12N2310/151 , C12N2310/18 , C12N2310/3125 , C12N2310/315 , C12N2310/321 , C12N2310/33 , C12N2310/346 , C12N2310/3517 , C12N2310/3521 , C12N2710/16622
摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.
摘要翻译： 提供组合物和方法用于治疗和诊断疱疹病毒感染。 根据优选实施方案，提供寡核苷酸，其与衍生自对应于开放阅读框UL5，UL8，UL9，UL20，UL27，UL29，UL20，UL27，UL29，UL30，UL42，UL52和IE175之一的疱疹病毒基因的RNA或DNA特异性杂交 单纯疱疹病毒1型。寡核苷酸包含足以实现所述特异性杂交的同一性和数目的核苷酸单元。 在其它优选实施方案中，寡核苷酸与翻译起始位点，编码区或5'-非翻译区具体杂交。 公开了治疗疑似被疱疹病毒感染的动物的方法，包括使动物与本发明的寡核苷酸接触。 公开了用于治疗由单纯疱疹病毒1型，2型单纯疱疹病毒，巨细胞病毒，人疱疹病毒6，爱泼斯坦巴尔病毒或水痘带状疱疹病毒引起的感染的方法。
-
2.发明授权
公开(公告)号：US5591720A
公开(公告)日：1997-01-07
申请号：US927506
申请日：1992-11-19
IPC分类号： A61K31/70 , A01N43/04 , A61K38/00 , A61K48/00 , A61P31/12 , C07H20060101 , C07H15/12 , C07H17/00 , C07H21/00 , C07K14/045 , C12N9/12 , C12N15/00 , C12N15/09 , C12N15/113 , C12P19/34 , C12Q1/68 , C12Q1/70 , G07H21/04
CPC分类号： A61K31/711 , C07K14/005 , C12N15/1133 , C12N9/1252 , C12Q1/705 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3521 , C12N2710/16122
摘要： Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.
摘要翻译： PCT No.PCT / US91 / 05815 Sec。 371日期：1992年11月19日 公开了用于调节巨细胞病毒（CMV）感染作用的组合物和方法，包括使CMV mRNA与寡核苷酸或寡核苷酸类似物接触，寡核苷酸或寡核苷酸类似物可与至少部分 CMV RNA。 根据优选实施方案，寡核苷酸或寡核苷酸类似物被设计为与编码IE1，IE2或DNA聚合酶蛋白的CMV mRNA的部分结合。 根据优选实施方案，公开了治疗人巨细胞病毒的方法。
-
公开(公告)号：US6153595A
公开(公告)日：2000-11-28
申请号：US838715
申请日：1997-04-09
IPC分类号： C12N15/09 , A61K31/712 , A61K38/00 , A61K48/00 , A61P31/22 , C07H21/00 , C07H21/04 , C07K14/045 , C12N9/12 , C12N15/113 , C12Q1/70 , C12Q1/68
CPC分类号： C12N15/1133 , A61K31/70 , A61K31/711 , C07H21/00 , C07K14/005 , C12N9/1252 , C12Q1/705 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/334 , C12N2310/346 , C12N2310/3521 , C12N2310/3525 , C12N2710/16122
摘要： This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2'-methoxyethoxy modification and may be chimeric oligonucleotides.
摘要翻译： 本发明涉及用于治疗CMV感染的组合物和方法。 提供反义寡核苷酸是有效的抗病毒剂。 在优选实施方案中，寡核苷酸含有至少一个2'-甲氧基乙氧基修饰，并且可以是嵌合寡核苷酸。
-
公开(公告)号：US07067497B2
公开(公告)日：2006-06-27
申请号：US10038335
申请日：2002-01-02
申请人： Ronnie C. Hanecak , Kevin P. Anderson , C. Frank Bennett , Ming-Yi Chiang , Vickie L. Brown-Driver , David J. Ecker , Timothy A. Vickers , Jacqueline R. Wyatt
发明人： Ronnie C. Hanecak , Kevin P. Anderson , C. Frank Bennett , Ming-Yi Chiang , Vickie L. Brown-Driver , David J. Ecker , Timothy A. Vickers , Jacqueline R. Wyatt
IPC分类号： C07H21/04 , A61K31/7115 , A61K31/712 , A61K31/7125
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.
-
公开(公告)号：US06423489B1
公开(公告)日：2002-07-23
申请号：US08452841
申请日：1995-05-30
申请人： Kevin P. Anderson , Ronnie C. Hanecak , Kazuya Hoshiko , Chikateru Nozaki , Tsukasa Nishihara , Hiroshi Nakatake , Fukusaburo Hamada , Tatsuo Eto , Shinichi Furukawa , Shoji Furusako , Thomas W. Bruice , Walter F. Lima
发明人： Kevin P. Anderson , Ronnie C. Hanecak , Kazuya Hoshiko , Chikateru Nozaki , Tsukasa Nishihara , Hiroshi Nakatake , Fukusaburo Hamada , Tatsuo Eto , Shinichi Furukawa , Shoji Furusako , Thomas W. Bruice , Walter F. Lima
IPC分类号： C12Q168
CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
-
6.发明授权Compositions and methods for treatment of Hepatitis C virus associated diseases 失效治疗丙型肝炎病毒相关疾病的组合物和方法公开(公告)号：US06433159B1
公开(公告)日：2002-08-13
申请号：US08823895
申请日：1997-03-17
申请人： Kevin P. Anderson
发明人： Kevin P. Anderson
IPC分类号： C07H2104
CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707
摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.
摘要翻译： 提供反义寡核苷酸，其与HCV RNA的至少一部分互补并且与其特异性杂交。 可以施用这些寡核苷酸以在体内或体外抑制丙型肝炎病毒的复制并治疗丙型肝炎病毒相关疾病。 这些化合物可以预防性地或治疗性地用于降低与丙型肝炎病毒相关的疾病的严重性。
-
7.发明授权Compositions and methods for treatment of hepatitis C virus-associated diseases 失效用于治疗丙型肝炎病毒相关疾病的组合物和方法公开(公告)号：US06608191B1
公开(公告)日：2003-08-19
申请号：US09690936
申请日：2000-10-18
IPC分类号： C07H2104
CPC分类号： C12N15/1131 , A61K38/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2770/24222 , C12Q1/707 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
摘要翻译： 提供反义寡核苷酸，其与至少一部分HCV RNA互补并可与其相互杂交，并能够抑制HCV RNA的功能。 可以施用这些寡核苷酸来体内或体外抑制丙型肝炎病毒的活性。 这些化合物可以预防性地或治疗性地用于降低与丙型肝炎病毒相关的疾病的严重性，以及HCV和HCV相关疾病的诊断和检测。 还公开了使用这些化合物的方法。
-
8.发明授权Compositions and methods for treatment of hepatitis C virus-associated diseases 失效用于治疗丙型肝炎病毒相关疾病的组合物和方法公开(公告)号：US06174868B1
公开(公告)日：2001-01-16
申请号：US08988321
申请日：1997-12-10
IPC分类号： A61K31711
CPC分类号： C12N15/1131 , A61K38/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2770/24222 , C12Q1/707 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
摘要翻译： 提供反义寡核苷酸，其与至少一部分HCV RNA互补并可与其相互杂交，并能够抑制HCV RNA的功能。 可以施用这些寡核苷酸来体内或体外抑制丙型肝炎病毒的活性。 这些化合物可以预防性地或治疗性地用于降低与丙型肝炎病毒相关的疾病的严重性，以及HCV和HCV相关疾病的诊断和检测。 还公开了使用这些化合物的方法。
-
公开(公告)号：US20110124715A1
公开(公告)日：2011-05-26
申请号：US12849886
申请日：2010-08-04
申请人： Ronnie C. Hanecak , Kevin P. Anderson , C. Frank Bennett , Ming-Yi Chiang , Vickie L. Brown-Driver , David J. Ecker , Timothy Vickers , Jacqueline R. Wyatt
发明人： Ronnie C. Hanecak , Kevin P. Anderson , C. Frank Bennett , Ming-Yi Chiang , Vickie L. Brown-Driver , David J. Ecker , Timothy Vickers , Jacqueline R. Wyatt
IPC分类号： A61K31/7088 , C12N7/00 , A61P31/16 , A61P31/18 , A61P31/22
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.
摘要翻译： 提供了具有保守的G4序列和足够数目的侧翼核苷酸以显着抑制病毒活性的修饰的寡核苷酸。 还提供了G4四重态寡核苷酸结构。 还提供了用于病毒相关疾病的预防，诊断和治疗方法。
-
公开(公告)号：US06995146B2
公开(公告)日：2006-02-07
申请号：US09853409
申请日：2001-05-11
IPC分类号： A61K31/711 , A61K31/7105 , C07H21/04 , C07H21/02
CPC分类号： C12N15/1131 , A61K38/00 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707 , C12N2310/3525
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.038 秒)
